Efficacy and safety of SGLT2 inhibitor, Ipragliflozin in type 2 diabetes patients. - Efficacy and Safety of SGLT2 inhibitor Ipragliflozin in type 2 diabetes patients.(ESST2)

Chubu-Rosai Hospital Department of Diabetes and Endocrinology0 个研究点目标入组 15 人开始时间: 2014年5月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patient who had myocardial infarction within the past six months. 2.Patient with a severe ketotic diabetic coma or precoma. 3.Patient with severe infectious disease (especially urinary tract infection), before and after operation, and a serious injury. 4.Patient with a past history of hypersensitivity for Ipragliflozin. 5.A pregnant woman or woman who may be pregnant. 6.Elderly person (>70 years). 7 Patient with hypoalimentation or dehydration. 8.Patient who is considered to be inappropriate by the chief physician. During the entire study period, when the chief physician judges that the continuing participation in this study became difficult, by aggravation such as HbA1c or blood glucose level and other factors, the appropriate treatment should be done immediately: administration of other antihyperglycemic agent or other appropriate measures.

发起方

Chubu-Rosai Hospital Department of Diabetes and Endocrinology